vs
LANDS' END, INC.（LE）与Pacira BioSciences, Inc.（PCRX）财务数据对比。点击上方公司名可切换其他公司
LANDS' END, INC.的季度营收约是Pacira BioSciences, Inc.的1.8倍（$317.5M vs $177.4M），Pacira BioSciences, Inc.净利率更高（1.6% vs 1.6%，领先0.0%），Pacira BioSciences, Inc.同比增速更快（5.0% vs 0.1%），过去两年Pacira BioSciences, Inc.的营收复合增速更高（-0.2% vs -0.9%）
Lands' End是1963年诞生于美国芝加哥的服饰零售品牌，最初以邮购游艇用品起家，目前业务拓展至服饰、箱包与家居用品领域。截至2024年2月，品牌在美国本土共开设26家门店，总部位于威斯康星州道奇维尔。品牌名源自地名兰兹角，因创立时印刷错了撇号位置又无力重印，错拼的名称便沿用至今。
Pacira BioSciences是一家专科制药企业，专注于非阿片类疼痛管理药物的研发与商业化，核心产品线面向术后镇痛场景，服务以美国为主的医院、门诊手术中心等医疗服务机构，同时推进部分国际市场的拓展工作。
LE vs PCRX — 直观对比
营收规模更大
LE
是对方的1.8倍
$177.4M
营收增速更快
PCRX
高出4.9%
0.1%
净利率更高
PCRX
高出0.0%
1.6%
两年增速更快
PCRX
近两年复合增速
-0.9%
损益表 — Q3 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $317.5M | $177.4M |
| 净利润 | $5.2M | $2.9M |
| 毛利率 | 51.8% | — |
| 营业利润率 | 5.3% | 3.9% |
| 净利率 | 1.6% | 1.6% |
| 营收同比 | 0.1% | 5.0% |
| 净利润同比 | 198.3% | — |
| 每股收益（稀释后） | $0.17 | $0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LEPCRX
| Q1 26 | — | $177.4M | ||
| Q4 25 | $317.5M | $196.9M | ||
| Q3 25 | — | $179.5M | ||
| Q2 25 | $261.2M | $181.1M | ||
| Q1 25 | — | $168.9M | ||
| Q4 24 | $318.6M | $187.3M | ||
| Q3 24 | $317.2M | $168.6M | ||
| Q2 24 | $285.5M | $178.0M |
净利润LEPCRX
| Q1 26 | — | $2.9M | ||
| Q4 25 | $5.2M | — | ||
| Q3 25 | — | $5.4M | ||
| Q2 25 | $-8.3M | $-4.8M | ||
| Q1 25 | — | $4.8M | ||
| Q4 24 | $-593.0K | — | ||
| Q3 24 | $-5.3M | $-143.5M | ||
| Q2 24 | $-6.4M | $18.9M |
毛利率LEPCRX
| Q1 26 | — | — | ||
| Q4 25 | 51.8% | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | 50.8% | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | 50.6% | 78.7% | ||
| Q3 24 | 47.9% | 76.9% | ||
| Q2 24 | 48.7% | 75.1% |
营业利润率LEPCRX
| Q1 26 | — | 3.9% | ||
| Q4 25 | 5.3% | 1.2% | ||
| Q3 25 | — | 3.5% | ||
| Q2 25 | -0.9% | 4.7% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | 2.9% | 13.2% | ||
| Q3 24 | 0.8% | -82.8% | ||
| Q2 24 | 0.8% | 15.9% |
净利率LEPCRX
| Q1 26 | — | 1.6% | ||
| Q4 25 | 1.6% | — | ||
| Q3 25 | — | 3.0% | ||
| Q2 25 | -3.2% | -2.7% | ||
| Q1 25 | — | 2.8% | ||
| Q4 24 | -0.2% | — | ||
| Q3 24 | -1.7% | -85.1% | ||
| Q2 24 | -2.3% | 10.6% |
每股收益（稀释后）LEPCRX
| Q1 26 | — | $0.07 | ||
| Q4 25 | $0.17 | $0.05 | ||
| Q3 25 | — | $0.12 | ||
| Q2 25 | $-0.27 | $-0.11 | ||
| Q1 25 | — | $0.10 | ||
| Q4 24 | $-0.02 | $0.38 | ||
| Q3 24 | $-0.17 | $-3.11 | ||
| Q2 24 | $-0.20 | $0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $36.3M | $144.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $231.0M | $653.9M |
| 总资产 | $852.7M | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LEPCRX
| Q1 26 | — | $144.3M | ||
| Q4 25 | $36.3M | $238.4M | ||
| Q3 25 | — | $246.3M | ||
| Q2 25 | $18.1M | $445.9M | ||
| Q1 25 | — | $493.6M | ||
| Q4 24 | $30.4M | $484.6M | ||
| Q3 24 | $25.6M | $453.8M | ||
| Q2 24 | $27.4M | $404.2M |
总债务LEPCRX
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益LEPCRX
| Q1 26 | — | $653.9M | ||
| Q4 25 | $231.0M | $693.1M | ||
| Q3 25 | — | $727.2M | ||
| Q2 25 | $230.1M | $757.8M | ||
| Q1 25 | — | $798.5M | ||
| Q4 24 | $223.6M | $778.3M | ||
| Q3 24 | $226.5M | $749.6M | ||
| Q2 24 | $234.6M | $879.3M |
总资产LEPCRX
| Q1 26 | — | $1.2B | ||
| Q4 25 | $852.7M | $1.3B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | $760.5M | $1.5B | ||
| Q1 25 | — | $1.6B | ||
| Q4 24 | $843.6M | $1.6B | ||
| Q3 24 | $802.5M | $1.5B | ||
| Q2 24 | $800.1M | $1.6B |
负债/权益比LEPCRX
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-15.7M | — |
| 自由现金流经营现金流 - 资本支出 | $-22.4M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 2.1% | — |
| 现金转化率经营现金流/净利润 | -3.03× | — |
| 过去12个月自由现金流最近4个季度 | $-55.0M | — |
8季度趋势，按日历期对齐
经营现金流LEPCRX
| Q1 26 | — | — | ||
| Q4 25 | $-15.7M | $43.7M | ||
| Q3 25 | — | $60.8M | ||
| Q2 25 | $-22.5M | $12.0M | ||
| Q1 25 | — | $35.5M | ||
| Q4 24 | $-17.1M | $33.1M | ||
| Q3 24 | $30.7M | $53.9M | ||
| Q2 24 | $-25.8M | $53.2M |
自由现金流LEPCRX
| Q1 26 | — | — | ||
| Q4 25 | $-22.4M | $43.5M | ||
| Q3 25 | — | $57.0M | ||
| Q2 25 | $-30.7M | $9.3M | ||
| Q1 25 | — | $26.9M | ||
| Q4 24 | $-27.8M | $31.0M | ||
| Q3 24 | $26.0M | $49.8M | ||
| Q2 24 | $-32.6M | $51.6M |
自由现金流率LEPCRX
| Q1 26 | — | — | ||
| Q4 25 | -7.1% | 22.1% | ||
| Q3 25 | — | 31.7% | ||
| Q2 25 | -11.8% | 5.1% | ||
| Q1 25 | — | 15.9% | ||
| Q4 24 | -8.7% | 16.6% | ||
| Q3 24 | 8.2% | 29.6% | ||
| Q2 24 | -11.4% | 29.0% |
资本支出强度LEPCRX
| Q1 26 | — | — | ||
| Q4 25 | 2.1% | 0.1% | ||
| Q3 25 | — | 2.2% | ||
| Q2 25 | 3.2% | 1.5% | ||
| Q1 25 | — | 5.1% | ||
| Q4 24 | 3.3% | 1.1% | ||
| Q3 24 | 1.5% | 2.4% | ||
| Q2 24 | 2.4% | 0.9% |
现金转化率LEPCRX
| Q1 26 | — | — | ||
| Q4 25 | -3.03× | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.82× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LE
| U Se Commerce | $179.8M | 57% |
| Business Outfitters Revenue | $78.8M | 25% |
| Licensing And Retail | $20.2M | 6% |
| Other | $19.8M | 6% |
| Third Party | $18.9M | 6% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
